Newly developed retatrutide, a dual -action drug targeting simultaneously GLP-1 and GIP receptors, is creating considerable buzz within the healthcare community. Early clinical studies have shown substantial reductions in overall size and improvements in metabolic markers for individuals with obesity . Researchers believe this unique approach m… Read More